Interferon Alpha Treatment and Immune Response in Bladder Cancer
Author Information
Author(s): L Molto, J Carballido, L Manzano, E Reyes, C Olivier, M Alvarez-Mon
Primary Institution: Hospital Universitario 'Principe de Asturias', University of Alcala de Henares, and Clinica 'Puerta de Hierro', Madrid, Spain
Hypothesis
Does prophylactic intracavitary treatment with interferon alpha enhance immune response in patients with superficial transitional cell carcinoma of the bladder?
Conclusion
Prophylactic intravesical instillations of interferon alpha 2b enhance interferon gamma production and decrease interleukin 4 production in patients with superficial transitional cell carcinoma of the bladder.
Supporting Evidence
- Patients showed significantly enhanced production of interferon gamma after treatment.
- Interleukin 4 production decreased significantly after treatment.
- Both cytokine levels returned to pretreatment levels one year after treatment.
Takeaway
This study shows that a treatment for bladder cancer can help the body produce more of a certain immune signal that fights cancer, while reducing another signal that might not help.
Methodology
Seventeen patients with superficial transitional cell carcinoma received weekly intracavitary instillations of interferon alpha 2b and were analyzed for immune response before, during, and after treatment.
Limitations
The study only included a small number of patients and lacked a control group receiving no treatment.
Participant Demographics
All participants were men, with a mean age of 66.2 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
90%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website